Compare AbbVie Inc (ABBV) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Diamondback Energy Inc — how do they compare? AbbVie Inc trades at $254.89 (market cap $449.91B), while Diamondback Energy Inc trades at $187.5 (market cap $50.79B). The key difference: AbbVie Inc is far larger — about 8.9× Diamondback Energy Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | FANG | |
|---|---|---|
Market Cap | $449.91B | $50.79B |
Sector | Health | Energy |
52-Week High | $261.07 | $213.69 |
52-Week Low | $184.85 | $134.53 |
Enterprise Value | $513.38B | $64.52B |
Dividend Yield | 2.72% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.
Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.
Diamondback Energy (FANG) trades at $180.56, up 4.95% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $14.93B in 2025 but faces declining net margins. Analyst consensus is overwhelmingly bullish with a $232.10 price target, supported by positive energy sector sentiment from Zacks and Seeking Alpha as of late June 2026.
FANG offers upside potential from high analyst targets and operational cash flow strength, but risks include volatile oil prices, margin compression, and technical resistance near $175. The stock's high P/E of 177.28 reflects growth expectations, yet execution on Q2 2026 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
